The product basket increased to 1800 medicines and 285 Surgical Equipment
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
Erdafitinib is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Good momentum in commercial CDMO business
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Subscribe To Our Newsletter & Stay Updated